New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization
RETT
Search for New Genes Involved in Molecular Etiology of Rett Syndrome Through Comparative Genomic Hybridization on DNA Microarrays
1 other identifier
interventional
17
1 country
9
Brief Summary
Rett syndrome (RTT) is a genetic encephalopathy and the typical form is caused by mutations in the gene MECP2. It is a genetically heterogeneous pathology. CDKL5 and FOXG1 have been recently discovered being involved in other forms of RTT. However, at least 5% of typical forms and more other atypical forms are not linked to any of 3 genes known to be involved in the disease. The purpose of this study is to identify new genes involved in molecular etiology of typical and atypical forms of RTT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2010
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 23, 2016
CompletedFirst Posted
Study publicly available on registry
August 31, 2016
CompletedAugust 31, 2016
August 1, 2016
1.2 years
August 23, 2016
August 26, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Analysis of chromosomal imbalances through comparative genomic hybridization on DNA microarrays
Search for pathogenic chromosomal imbalance
up to 12 months
Study Arms (2)
RTT patient
EXPERIMENTALBlood sampling
Parents
EXPERIMENTALBlood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
Interventions
In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
Eligibility Criteria
You may qualify if:
- Patients: RETT syndrome
- Patients: Female
- Parents: parent of a patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Handicaps de l'Enfant - Pavillon Ste Marie, CHU St Jacques
Besançon, France
Service de Neuropédiatrie, Hôpital St Jacques, CHU de Besançon
Besançon, France
Unité de génétique, Groupe hospitalier Hôpital Flaubert
Caen, France
Centre de Génétique Hôpital d'Enfants, CHU de Dijon
Dijon, France
Service de neuropédiatrie, CHU Hôpital Gui de Chauliac
Montpellier, France
Laboratoire de Génétique chromosomique, CHU Hôpital l'Archet 2
Nice, France
Service de génétique médicale, CHU Hôpital Purpan
Nice, France
Service de génétique médicale, CHU Hôpital Purpan, CHU de Toulouse
Toulouse, France
Laboratoire de Génétique, Hôpitaux de Brabois, CHU de Nancy
Vandœuvre-lès-Nancy, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christophe PHILIPPE,
Laboratoire de Génétique Médicale, Rue du Morvan, 54511 Vandoeuvre-Les-Nancy Cédex
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 23, 2016
First Posted
August 31, 2016
Study Start
February 1, 2010
Primary Completion
May 1, 2011
Study Completion
May 1, 2011
Last Updated
August 31, 2016
Record last verified: 2016-08
Data Sharing
- IPD Sharing
- Will not share